| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | 0.025 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | Vorinostat | FIMM | pan-cancer | AAC | 0.017 | 0.9 |